Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

NCT ID: NCT02529449

Last Updated: 2024-11-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-01
• Study Completion Date: 2016-03-19

Brief Summary

The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.

Conditions

Type 1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

once daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral

ASP1941 Low dose group

once daily

Group Type: EXPERIMENTAL

ASP1941

Intervention Type: DRUG

Oral

ASP1941 Middle dose group

once daily

Group Type: EXPERIMENTAL

ASP1941

Intervention Type: DRUG

Oral

ASP1941 High dose group

once daily

Group Type: EXPERIMENTAL

ASP1941

Intervention Type: DRUG

Oral

Interventions

Placebo

Oral

Intervention Type: DRUG

ASP1941

Oral

Intervention Type: DRUG

Other Intervention Names

Suglat; Ipragliflozin

Eligibility Criteria

Inclusion Criteria

At the time of obtaining informed consent:

• Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
• Subject is able to be admitted to the site as scheduled.
• Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.

At screening period:

• Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
• Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
• Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
• Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
• Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.

Exclusion Criteria

At the time of obtaining informed consent:

• Subject has type 2 diabetes mellitus.
• Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
• Subject has received ASP1941 (ipragliflozin) with the exception of placebo.

At screening period:

• Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
• Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
• Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
• Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
• Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
• Subject with perioperative, severe infection or serious injury.
• Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
• Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
• Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
• Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
• Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
• Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
• Subject has urinary tract infection or genital infection with subjective symptoms.
• Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
• Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
• Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
• Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
• Subject has psychiatric disorder that makes the subject unsuitable for study participation.
• Subject has drug addiction or alcohol abuse.
• Subject has a history of drug allergies.
• Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
• Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
• Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Inc

Locations

Site JP00006

Aichi, , Japan

Site JP00002

Fukuoka, , Japan

Site JP00009

Gunma, , Japan

Site JP00001

Ibaraki, , Japan

Site JP00005

Kanagawa, , Japan

Site JP00008

Kanagawa, , Japan

Site JP00003

Okayama, , Japan

Site JP00004

Osaka, , Japan

Site JP00010

Osaka, , Japan

Site JP00011

Osaka, , Japan

Site JP00007

Tokyo, , Japan

Countries

Japan

References

Toyoshima J, Saito M, Kaibara A, Isaka H, Sakatani T. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus. Clin Ther. 2020 Sep;42(9):1787-1798.e3. doi: 10.1016/j.clinthera.2020.07.009. Epub 2020 Aug 21.

Reference Type: DERIVED

PMID: 32839028 (View on PubMed)

Related Links

https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=307

Link to results on the Astellas Clinical Study Results website

Other Identifiers

1941-CL-6001

Identifier Type: -

Identifier Source: org_study_id